News & Updates

Show Multimedia Only

First-line SGLT2 inhibitors, GLP1 receptor agonists need to cut price to be cost-effective

15 Oct 2022

First-line treatment with sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP1) receptor agonists improves outcomes in patients with type 2 diabetes (T2D), but to be cost-effective, the prices of these drugs must drop by at least 70 percent, suggests a study.

15 Oct 2022

Pemetrexed-based chemo boosts survival in NSCLC

15 Oct 2022

As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.

15 Oct 2022

Lipid profile tied to outcomes in lung squamous cell carcinoma

15 Oct 2022

Among patients with lung squamous cell carcinoma (LUSC), lower levels of high-density lipoprotein cholesterol (HDL-C) appear to aggravate the risk of worse outcomes, a recent study has found.

15 Oct 2022

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

15 Oct 2022 by

Adjuvant chemotherapy with a modified dose of FOLFIRINOX (mFOLFIRINOX) was associated with significantly better survival outcomes, particularly disease-free survival (DFS) and overall survival (OS), compared with single-agent gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC), according to a 5-year analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6* study.

15 Oct 2022

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

15 Oct 2022

Updated BEST results: No major difference between EES or CABG for multivessel disease

14 Oct 2022 by

In patients with multivessel coronary artery disease, the risk of any-cause death, myocardial infarction (MI), or target vessel revascularization (TVR) did not vary according to whether patients underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES) or coronary artery bypass graft (CABG), extended follow-up of the BEST* trial showed.

14 Oct 2022

Pre-DAA IL-1β can predict HBV reactivation in HCV

14 Oct 2022

Among hepatitis C virus (HCV) patients with resolved hepatitis B virus (HBV) infections, levels of interleukin (IL)-1β before the initiation of direct-acting antiviral (DAA) treatment may help predict HBV reactivation, reports a recent study.

14 Oct 2022

DIY diabetes management with digital app facilitates better weight, blood sugar control

14 Oct 2022 by

Self-management of diabetes through smartphone heath app engagement appears to bring positive changes in disease outcomes such as weight and blood sugar, according to data from the Diabetes Lifestyle Intervention using Technology Empowerment (D’LITE) study.